近期，"国家喊你减肥"成为网络热议焦点。 在今年全国两会期间，国家卫健委主任雷海潮在新闻发布会上用7分钟专门阐述了体重管理的重要性，并表示将持续推进"体重管理年"相关举 措，推动政府、行业、单位和个人共同落实责任。 记者注意到，自去年6月国家卫健委等16个部门联合发布《"体重管理年"活动实施方案的通知》后，去年下半年起，多个省份陆续出台了本 地"体重管理年"实施细则，许多地方还明确提出了降低居民肥胖率的具体目标。 ▍多地晒出居民肥胖率并明确减肥目标 在各地陆续发布的"体重管理年"活动实施方案中，许多地方都详细披露了本地区居民的肥胖现状。 例如，浙江省数据显示，当地居民超重和肥胖率高达47.6%，急需采取措施进行干预和改善；甘肃方面则介绍，2023年全省成人超重率为 36.14%，其中60岁以上老年人成为肥胖高发人群；新疆披露，自治区成年居民超重率为34.05%，肥胖率达到24.20%；广东也表示，约有四成 成年人属于超重或肥胖，整体形势依然严峻。针对当前的肥胖率，多个省份还制定了明确的减重目标。例如，新疆提出，以2019—2023年超重 率和肥胖率年均增幅为基线，2024—2026年期间，成年人及儿童青少年的 ...

整理 | GLP1减重宝典内容团队 "这些药物并非灵丹妙药。它们不会立即改变你的习惯或生活方式，"她指出。 Janelle Rohner 通过记录自己的减肥历程，在社交媒体上积累了大量粉丝。她分享了一些非常规的减肥技巧，比如用甜椒代替三明治面包，并 开设了一门售价 200 美元的宏量营养素课程。 然而，当她最近透露自己减肥的部分原因是使用 GLP-1 药物时，网友们迅速反应强烈，批评之声不绝于耳。 "如果你在使用 GLP-1 药物的同时推销减肥方案，就需要坦诚相告，"一位评论者在 Rohner 披露自己使用该药物的 YouTube 视频下写道。"服 用 GLP-1 药物本身不是问题，问题在于不公开信息就推销课程。" 这些强烈反对凸显了网红与受众之间脆弱的关系，信任至关重要，真实性也受到严格审查。这也凸显了 GLP-1 药物在健康和饮食领域日益重 要的颠覆性作用。 点击关注，追踪最新GLP-1资讯 这段视频通过她拥有超过500万粉丝的TikTok频道进行推广。在视频中，罗纳承认公开谈论自己的决定非常困难。 "关注我一段时间的朋友们都知道，我什么都试过了——生酮饮食、宏观追踪、锻炼、改变生活方式。我一直对哪些方法 ...

整理 | GLP1减重宝典内容团队 GLP-1（胰高血糖素样肽-1）是一种由肠道L细胞分泌的激素，属于肠促胰岛素家族的重要成员。它在人体中扮演着关键角色：许多食物在消化 过程中会自然刺激GLP-1的分泌。这种激素能够减缓胃肠蠕动，延长胃排空时间，并有效抑制食欲，从而在调节血糖和控制体重方面发挥重要作 用。 近年来，全球范围内GLP-1类药物的研发取得了显著进展。其中，丹麦诺和诺德公司推出的司美格鲁肽（Semaglutide）备受关注。其降糖版本 名为"诺和泰"（Ozempic），减重版本名为"诺和盈"（Wegovy），而口服版本则名为"诺和忻"（Rybelsus）。与此同时，美国礼来公司研发的替 西帕肽（Tirzepatide）也崭露头角，其降糖减重通用商品名为"穆峰达"（Mounjaro）。 点击关注，追踪最新GLP-1资讯 值得关注的是， 诺和忻是全球首个且目前唯一的口服GLP-1受体激动剂（GLP-1RA），目前有3mg、7mg和14mg三种规格。 接下来，我们将 基于最新研究成果，深入剖析诺和忻的独特优势，并对比其与诺和泰、诺和盈之间的差异，以期为糖尿病患者和减重人群提供更具针对性的治疗 选择。 ▍口 ...

整理 | GLP1减重宝典内容团队 关于ASC47-103研究 ASC47-103研究在美国开展，是一项随机、双盲、安慰剂对照的临床研究，旨在评估单剂量超长效皮下注射（SQ）ASC47联合 司美格鲁肽治 疗肥胖症（体质指数≥30 kg/m²）患者的安全性和初步疗效。ASC47-103研究包含三个队列：队列1的参与者将接受单剂量10 mg ASC47或容量 匹配的安慰剂皮下注射，以及四剂 司美格鲁肽（0.5 mg，每周一次）皮下注射。队列2的参与者将接受单剂量30 mg ASC47或容量匹配的安慰 剂皮下注射，以及四剂 司美格鲁肽（0.5 mg，每周一次）皮下注射。第 3 组参与者将通过皮下注射接受单剂量 60 毫克 ASC47 或体积匹配的 安慰剂，并通过皮下注射接受四剂量的司美格鲁肽（0.5 毫克，每周一次）。 *本文仅供医疗卫生专业人士参考 版权声明：所有「GLP1减重宝典」的原创文章，转载须联系授权，并在文首/文末注明来源、作者、微信ID，否则减重宝典将向其追究法律责 任。部分文章推送时未能与原作者或公众号平台取得联系。若涉及版权问题，敬请原作者联系我们。合作事宜，请添加微信：andyxu365 歌礼制 ...

Core Viewpoint - The article discusses the increasing focus on obesity management in China, highlighting the government's initiatives and the societal response to the obesity epidemic, which is recognized as a public health issue rather than just a personal choice [4][5][10]. Group 1: Government Initiatives - The National Health Commission announced a three-year "Weight Management Year" initiative during the National People's Congress, leading to a surge in demand for weight management clinics [4]. - By June 2025, comprehensive hospitals and children's hospitals are required to implement weight management clinics, with encouragement for stronger hospitals to establish obesity prevention centers [5]. - The government's emphasis on obesity management is seen as a significant shift, moving from mere advocacy to actionable policies as part of the "Healthy China 2030" plan [18][20]. Group 2: Societal Response and Challenges - There is a growing trend in society towards weight loss, with various brands launching weight loss campaigns, indicating a cultural shift towards health consciousness [5]. - Despite the push for weight management, many individuals struggle with maintaining lifestyle changes necessary for weight loss, often reverting to old habits [7][9]. - The article emphasizes that obesity is a complex issue influenced by social, economic, and psychological factors, making it difficult for individuals to manage weight solely through personal willpower [9][15]. Group 3: Health Implications - Obesity is linked to over 200 health issues and significantly increases the risk of 13 types of cancer, with global obesity rates rising dramatically [10][12]. - The article cites alarming statistics, such as one in eight people globally suffering from obesity and millions dying from obesity-related diseases [10][12]. - The chronic nature of obesity and related diseases poses a long-term public health challenge, with previous interventions showing limited effectiveness [12][13]. Group 4: Systemic Solutions - Experts argue that addressing obesity requires a systemic approach, involving not just healthcare providers but also changes in the food industry and public health policies [20][21]. - There is a call for better integration of health education and community support to encourage healthier lifestyles, as well as the need for accountability in health initiatives [21]. - The article highlights the importance of creating an environment conducive to healthy living, including access to nutritious food and opportunities for physical activity [21].

Core Viewpoint - The article highlights the urgent need for weight management in response to rising obesity rates, particularly in the U.S., and discusses the underlying causes and potential solutions in the context of health and economic implications [4][5]. Group 1: Obesity in the U.S. - The obesity rate among U.S. adults is alarming, with 78 million individuals having a BMI over 30, resulting in a 41.9% obesity rate [5]. - Annual deaths due to obesity range from 150,000 to 300,000, surpassing deaths from gun violence [5]. Group 2: Causes of Obesity - The rise of modern agriculture has led to increased food availability and lower prices, contributing to obesity [7]. - Capital-driven changes in dietary habits, particularly the dominance of corn in the food supply, have altered American diets, leading to higher caloric intake [8]. - The proliferation of sugar and high fructose corn syrup in American foods has significantly increased caloric consumption, with unhealthy eating habits being established from childhood [9]. Group 3: Health Expenditure and Governance - The U.S. has a high per capita healthcare expenditure of 96,000 RMB, which is 16 times that of China, yet life expectancy is only 78 years, indicating systemic governance issues beyond diet [10]. Group 4: Weight Management Strategies - Over half of U.S. adults attempt to lose weight annually, with similar trends observed in the UK, Australia, and Canada [11]. - The weight management sector is growing, focusing on two main strategies: caloric intake control and increased physical activity [13]. Group 5: Pharmaceutical Innovations - Major pharmaceutical companies like Eli Lilly and Novo Nordisk are leading in the development of GLP-1 drugs, which suppress appetite and are gaining market traction [13]. - The market for weight loss drugs is projected to exceed $100 billion by 2030, driven by high demand and significant efficacy [15]. Group 6: Government Support and Policy Changes - A new executive order by President Trump aims to reduce drug prices, potentially making weight loss medications more accessible to the general public [16]. Group 7: Personalized Weight Management - The demand for personalized weight management solutions is rising, with platforms like Noom and WeightWatchers offering tailored advice and support [17]. - Applications for calorie and exercise tracking are also in high demand, with many users actively monitoring their intake [19]. Group 8: Technological Advancements - The emergence of wearable technology and biotechnology is enhancing the personalization and effectiveness of weight management solutions [21]. - Comprehensive solutions like ZOE utilize blood monitoring to provide tailored nutritional advice, reflecting a shift towards more scientific approaches in weight management [21].

整理 | GLP1减重宝典内容团队 ▍改善 肥胖和糖尿病患者生活质量，司美格鲁肽提升精神健康 伦敦国王学院精神病学、心理学和神经科学研究所 (IoPPN) 的一项重要的新荟萃分析发现， 胰高血糖素样肽 1 受体激动剂 (GLP1-RAs) （一类用于治疗肥胖和糖尿病的药物）也可能有益于超重使用者的情绪健康。 这项发表在《美国医学会杂志·精神病学》(JAMA Psychiatry) 上的研究明确表示，使用 GLP1-RAs（例如司美格鲁肽）不会增加精神不 良事件的风险或加重抑郁症状。 肥胖和/或糖尿病患者患抑郁症等心理健康问题的风险更高。这可能会产生连锁反应，导致患者对身体健康药物的依从性降低、血糖控制 不佳，以及肥胖和糖尿病相关健康并发症的风险增加。尽管一些卫生机构 对 GLP1-RAs 可能带来的负面心理影响表示担忧，但这些报告并不一致。 伦敦国王学院IoPPN临床讲师、该研究的资深作者托比·皮林格博士表示："肥胖和糖尿病会对身心健康造成严重损害。我们对大量临床 试验数据的分析表明，GLP-1RA不仅从精神科角度来看是安全的，而且可能改善心理健康状况。" "随着这些药物的使用不断增长，我们的研究结果为患者和 ...

Core Viewpoint - CureGene's CG-0416 demonstrates significant potential as a dual mechanism candidate drug for treating Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) and obesity, showing a 58% reduction in liver lipid accumulation, a 66% improvement in weight loss, and a 50% decrease in muscle loss compared to standard therapies [2][4]. Group 1: Breakthroughs in Treatment - CG-0416 overcomes limitations of current GLP-1 receptor agonists by precisely targeting complementary metabolic pathways, enhancing weight control and muscle preservation [3]. - The liver-specific activation of CG-0416 results in a 20-fold higher concentration of active metabolites in the liver compared to peripheral tissues, maximizing safety [4]. - In a 26-week diet-induced obesity mouse model, CG-0416 combined with low-dose semaglutide showed a 66% reduction in fat mass and a muscle fat reduction ratio of 0.18 kg/kg, compared to existing therapies which range from 0.35 to 0.63 kg/kg [4]. Group 2: Clinical Translation Advantages - CG-0416 enhances GLP-1-mediated liver lipid oxidation while activating the IGF-1/Akt/FOXO3a axis to inhibit muscle catabolism, showcasing a dual pathway synergistic effect [4]. - With an oral bioavailability of 92%, CG-0416 is expected to be the first oral therapy used in conjunction with GLP-1 agonists, significantly higher than previously approved THR-β therapies [5]. Group 3: About CG-0416 - CG-0416 is a novel liver-targeted THR-β prodrug under development for treating MASH and obesity-related complications, demonstrating superior metabolic control compared to Resmetirom and VK-2809 in preclinical studies [6]. - As a potential oral adjunct to GLP-1 therapy, CG-0416 combines rapid fat loss with muscle preservation, positioning it as a next-generation metabolic modulator [6]. Group 4: About CureGene - Founded in 2018, CureGene is a biotechnology company based in China with a global focus, specializing in innovative platforms for cardiovascular and antiviral diseases [8]. - The company has successfully transitioned from a research-stage startup to a clinical-stage biotech firm, with a pipeline of drugs showing significant market potential and complete global intellectual property rights [8].

Core Viewpoint - The article highlights the fragmented nature of the U.S. healthcare system, particularly in the context of obesity treatment and the introduction of GLP-1 drugs like Ozempic and Wegovy, which have transformed the understanding of obesity from a matter of willpower to a chronic disease linked to various serious health conditions [2][4]. Group 1: Access to GLP-1 Drugs - Access to GLP-1 drugs is severely limited for many patients due to inconsistent insurance coverage, complex pre-approval processes, and opaque drug benefit management networks [4][5]. - The high out-of-pocket cost for these drugs can exceed $1,000 per month, making them unaffordable for most individuals [4]. - The rise of compounded drugs, produced by loosely regulated supply chains, poses safety and efficacy risks as patients seek more affordable options [5]. Group 2: Impact on Healthcare Providers - The pressure from compounded drugs has led original drug manufacturers like Eli Lilly and Novo Nordisk to offer lower-cost options and telehealth services [5]. - Access to medical services is often dictated by complex insurance standards rather than patient needs or medical expertise, undermining the authority of healthcare providers [5][6]. - The bureaucratic nature of the system forces doctors to adjust diagnoses to meet arbitrary insurance criteria, which can delay necessary interventions [5]. Group 3: Systemic Issues and Public Sentiment - Efforts to regulate and lower the cost of GLP-1 drugs have been limited, with the pharmaceutical industry maintaining high prices and insurance companies reluctant to provide broad coverage [6]. - Millions of Americans seeking obesity treatment face a dilemma between financial stability and health, highlighting a critical flaw in the healthcare system [6]. - The article argues that unless the systemic flaws in healthcare are addressed, the cycle of high costs, poor outcomes, and growing public anger will continue [6].

2025年5月17日至23日是第十一届全民营养周，今年的主题定为："吃动平衡 健康体重 全民行动"。今年还将继续推进"体重管理年"专项行动， 进一步推广健康的生活方式。"国家喊你减肥"这一话题早已深入人心，凸显了我国肥胖问题的严重性。 国家卫生健康委面向社会发布的《体重管理指导原则（2024年版）》提到，有研究预测，如果不加以有效控制，到2030年我国成人超重和肥胖 率将高达70.5%，儿童超重和肥胖率也将达到31.8%。 许多人仍然认为肥胖只是"外形不美观"，但实际上，肥胖是一种隐匿的代谢危机。它不仅危害身体健康，还会带来经济负担、时间损耗，甚至 增加机会成本。 的肥胖率上升了1.8%，女孩则略有下降。研究还指出， 肥胖的儿童在成年后大多仍然肥胖，相关慢性疾病也呈现出年轻化的趋势 。 肥胖从来不是一个"单一的指标"，而是众多疾病的起点。只要BMI超过正常范围，高血压、糖尿病、脂肪肝、肿瘤等慢性病便会如多米诺骨牌 般接踵而至。这些健康问题不仅严重损害生活质量，更会直接影响健康寿命的长短。 ▍肥胖其实是"富贵病" 许多人把肥胖调侃为"富贵病"，觉得不过是"吃得好"带来的身材变化，甚至认为"胖点没什么大碍"。可当 ...